Recent advances in the treatment of gestational diabetes

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1103-1111

  Agarwal, Mukesh M ^a   Punnose, John ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b AL AIN HOSPITAL   (United Arab Emirates)

Author keywords

Antihyperglycaemic drugs; Gestational diabetes; Insulin; Pregnancy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING DRUG; METFORMIN; NEW DRUG; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; SHORT ACTING DRUG; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

BLOOD GLUCOSE MONITORING; BLOOD PLACENTA BARRIER; CLINICAL TRIAL; DIABETIC RETINOPATHY; DIETARY INTAKE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG COST; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; EXERCISE; FEMALE; FETUS RISK; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; LIVER TOXICITY; MEDICAL RESEARCH; NONHUMAN; PREGNANCY DIABETES MELLITUS; REVIEW; SCREENING TEST; TERATOGENICITY; WEIGHT REDUCTION;

ANIMALS; DIABETES, GESTATIONAL; EXERCISE THERAPY; FEMALE; HUMANS; INSULIN; PREGNANCY;

EID: 4544375135     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1103     Document Type: Review

References (92)

1. AMERICAN DIABETES ASSOCIATION: Gestational diabetes mellitus. Position statement. Diab. Care (2004) 27(Suppl. 1):S88-S90.
2. GREENE MF: Screening for gestational diabetes mellitus. N. Engl. J. Med. (1997) 337:1625-1626.
3. HANNA FW, PETERS JR: Screening for gestational diabetes; past, present and future. Diabetic Med. (2002) 19:351-358.
4. KOUSSEFF BG: Gestational diabetes mellitus (class A): a human teratogen? Am. J. Med. Genet. (1999) 83:402-408.
5. BEN-HAROUSH A, YOGEV Y, HOD M: Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet. Med. (2004) 21:103-113.
6. O'SULLIVAN JB, MAHAN CM: Criteria for the oral glucose tolerance test in pregnancy. Diabetes (1964) 13:278-285.
7. VOGEL N, BURNAND B, VIAL Y et al.: Screening for gestational diabetes: Variation in guidelines. Eur. J. Obstet. Gynecol. Reprod. Biol. (2000) 91:29-36.
8. WORLD HEALTH ORGANIZATION: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO Consultation, Geneva: WHO (1999).
9. AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS: Clinical management guidelines for obstetrician-gynecologists. Gestational diabetes. ACOG Practice Bulletin 30. Obstet. Gynecol. (2001) 98:525-538.
10. CANADIAN DIABETES ASSOCIATION CLINICAL PRACTICE GUIDELINES EXPERT COMMITTEE: Guidelines for the prevention and management of diabetes in canada. Can. J. Diabetes (2003) 27(Suppl 2):S99-S105.
11. THE AUSTRALIAN DIABETES IN PREGNANCY SOCIETY: Gestational diabetes mellitus guidelines. Med. J. Australia (1998) 169:93-97.
12. AGARWAL MM, PUNNOSE J: Gestational diabetes; implications of variation in diagnostic criteria. Int. J. of Gynecol. Obstet. (2002) 78:45-46.
13. BRODY SC, HARRIS R, LOHR K: Screening for gestational diabetes: a summary of the evidence for the US Preventive Services Task Force. Obstet. Gynecol. (2003) 101:380-392.
14. KJOS SL, BUCHANAN TA: Gestational diabetes mellitus. N. Engl. J. Med. (1999) 341:1749-1756.
15. LANDO H: The new 'designer' insulins. Clinical Diabetes (2000) 18:154.
16. GARCIA-BOURNISSEN F, FEIG DS, KOREN G: Maternal-fetal transport of hypoglycaemic drugs. Clin. Pharmacokinet. (2003) 42:303-313.
17. GAMSON K, CHIA S, JOVANOVIC L: The safety and efficacy of insulin analogs in pregnancy. J. Matern. Fetal Neonatal Med. (2004) 15:26-34.
18. PEDERSEN J: Weight and length at birth of infants of diabetic mothers. Acta Endocrinol. (1954) 16:330-342.
19. GRECO P, VIMERCATI A, HYETT J et al.: The ultrasound assessment of adipose tissue deposition in fetuses of 'well controlled' insulin-dependent diabetic pregnancies. Diabet. Med. (2003) 20:858-862.
20. MIMOUNI F, MIODOVNIK M, SIDDIGI TA et al.: Perinatal asphyxia in infants of insulin-dependent diabetic mothers. J. Pediatr. (1988) 113:345-353.
21. GREENE MF: Oral hypoglycemic drugs for gestational diabetes. N. Engl. J. Med. (2000) 343:1178-1179.
22. SCHAEFER-GRAF UM, BUCHANAN TA, XIANG A et al.: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by Type 2 and gestational diabetes. Am. J. Obstet. Gynecol. (2000) 182:313-320.
23. SERMER M, NAYLOR CD, GARE DJ et al.: Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am. J. Obstet. Gynecol. (1995) 173:146-156.
24. RUMBOLD AR, CROWTHER CA: Women's experiences of being screened for gestational diabetes mellitus. Aust. N. Z. J. Obstet. Gynaecol. (2002) 24:131-137.
25. HAPO STUDY COOPERATIVE RESEARCH GROUP: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int. J. Gynaecol. Obstet. (2002) 78:69-77.
26. PARRETTI E, MECACCI F, PAPINI M et al.: Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care (2001) 24:1319-1323.
27. JOVANOVIC L: Point: yes, it is necessary to rely entirely on glycemic values for the insulin treatment of all gestational diabetic women. Diabetes Care (2003) 26:946-947.
28. DE VECIANA M, MAJOR CA, MORGAN MA et al.: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N. Engl. J. Med. (1995) 333:1237-1241.
29. BUCHANAN TA, KJOS SL COUNTERPOINT: Glucose monitoring in gestational diabetes: lots of heat, not much light. Diabetes Care (2003) 26:948-949.
30. DREXEL H, BICHLER A, SAILER S et al.: Prevention of perinatal morbidity by tight metabolic control in gestational diabetes mellitus. Diabetes Care (1988) 11:761-768.
31. TUROK DK, RATCLIFFE SD, BAXLEY EG: Management of gestational diabetes mellitus. Am. Fam. Physician (2003) 68:1767-1772.
32. DORNHORST A: Gestational diabetes: the unanswered questions. Clin. Nutr. (2003) 12:53-57.
33. DORNHORST A, FROST G: The principles of dietary management of gestational diabetes: reflection on current evidence. J. Hum. Nutr. Diet (2002) 15:145-156.
34. LANGER O: Management of gestational diabetes. Clin. Obstet. Gynecol. (2000) 43:106-115.
35. SCHOLL TO, HEDIGER ML, SCHALL JI et al.: Gestational weight gain, pregnancy outcome, and postpartum weight retention. Obstet. Gynecol. (1995) 86:423-427.
36. MOSES RG: The recurrence rate of gestational diabetes in subsequent pregnancies. Diabetes Care (1996) 19:1348-1350.
37. BRANKSTON GN, MITCHELLI BF, RYAN EA et al.: Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am. J. Obstet. Gynecol. (2004) 190:188-193.
38. REECE EA, HOMKO CJ: Diabetes mellitus in pregnancy. What are the best treatment options? Drug Saf. (1998) 18:209-220.
39. BHATTACHARYYA A, BROWN S, HUGHES S et al.: Insulin lispro and regular insulin in pregnancy. QJM (2001) 94:255-260.
40. McFARLAND MB, LANGER O, CONWAY DL et al.: Dietary therapy for gestational diabetes: how long is long enough? Obstet. Gynecol. (1999) 93:978-982.
41. GIUFFRIDA FMA, CASTRO AA, ATALLAH AN et al.: Diet plus insulin compared to diet alone in the treatment of gestational diabetes mellitus: A systematic review. Braz. J. Med. Biol. Res, (2003) 36:1297-1300.
42. NACHUM Z, BEN-SHLOMO I, WEINER E et al.: Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. Br. Med. J. (1999) 319:1223-1227.
43. MENON RK, COHEN RM, SPERLING MA et al.: Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia. N. Engl. J. Med. (1990) 323:309-315.
44. BALSELLS M, CORCOY R, MAURICIO D et al.: Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes. Diabetes Care (1997) 20:1172-1175.
45. LANDAUER W, CLARK EM: Teratogenic interaction of insulin and 2-deoxy-D-glucose in chick development. J. Exp. Zool. (1962) 151:245-252.
46. REAM JR, WEINGARTERN PL, PAPPAS AM: Evaluation of the prenatal effects of massive closes of insulin in rats. Teratology (1970) 3:29-32.
47. PHELPS RL, SAKOL P, METZGER BE et al.: Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch. Qphthalmol. (1986) 104:1806-1810.
48. BEST RM, CHAKRAVARTHY U: Diabetic retinopathy in pregnancy. Br. J. Ophthalmol. (1997) 81:249-451.
49. MASSON EA, PATMORE JE, BRASH PD et al.: Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet. Med. (2003) 20:46-50.
50. MECACCI F, CARIGNANI L, CIONI R et al.: Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur. J. Obstet. Gynecol. Reprod Biol. (2003) 111:19-24.
51. DIAMOND T, KORMAS N: Possible adverse fetal effect of insulin lispro. N. Engl. J. Med. (1997) 337:1009.
52. JOVANOVIC L, ILIC S, PETTITT DJ 3rd et al.: Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care (1999) 22:1422-1427.
53. BOSKOVIC R, FEIG DS, DEREWLANY L et al.: Transfer of insulin lispro across the human placenta: In vitro perfusion studies. Diabetes Care (2003) 26:1390-1394.
54. KITZMILLER JL, MAIN E, WARD B et al.: Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care (1999) 22:874-876.
55. BUCHBINDER A, MIODOVNIK M, KHOURY J et al.: Is the use of insulin lispro safe in pregnancy? J. Matern. Fetal Neonatal Med. (2002) 11:232-237.
56. LOUKOVAARA S, IMMONEN I, TRAMP KA et al.: Progression of retinopathy during pregnancy in Type 1 diabetic women treated with insulin lispro. Diabetes Care (2003) 26:1193-1198.
57. KURTZHALS P, SCHAFFER L, SORENSEN A et al.: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49:999-1005.
58. PETTITT DJ, OSPINA P, KOLACZYNSKI JW A et al.: Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care (2003) 26:183-186.
59. CIARALDI TP, CARTER L, SEIPKE G et al.: Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J. Clin. Endocrinol. Metab. (2001) 86:5838-5847.
60. HOLSTEIN A, PLASCHKE A, EGBERTS EH: Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Diabet. Med. (2003) 20:779-780.
61. DEVLIN JT, HOTHERSALL L, WILKIS JL: Use of insulin glargine during pregnancy in a Type 1 diabetic woman. Diabetes Care (2002) 25:1095-1096.
62. GRAY RS, COWAN P, STEEL JM et al.: Insulin action and pharmacokinetics in insulin treated diabetics during the third trimester of pregnancy. Diabet. Med. (1984) 1:273-738.
63. JOVANOVIC L: Optimization of insulin therapy in patients with gestational diabetes. Endocr. Pract. (2000) 6:98-100.
64. MERLOB P, LEVITT O, STAHL B: Oral antihyperglycemic agents during pregnancy and lactation: a review. Paediatr. Drugs (2002) 4:755-760.
65. FANELLI CG, B BOLLI GB: Sulphonylureas and pregnancy. Eur. J. Endocrinol. (1998) 138: 615-616.
66. SMOAK IW, EMANUEL AN: Tolbutamide placental transfer, tissue distribution, and metabolic effects in murine embryos. Pharmacol. Toxicol. (1998) 82:203-208.
67. HELLMUTH E, DAMM P, MOLSTED-PEDERSEN L: Congenital malformations in offspring of diabetic women treated with oral hypoglycaemic agents during embryogenesis. Diabet. Med. (1994) 11:471-474.
68. PIACQUADIO K, HOLLINGSWORTH DR, MURPHY H: Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet (1991) 338(8771):866-869.
69. TOWNER D, KJOS SL, LEUNG B et al.: Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care (1995) 18:1446-1451.
70. CHRISTESEN HB, MELANDER A: Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. Eur. J. Endocrinol. (1998) 138:698-701.
71. KEMBALL ML, McIVER C, MILNER RD et al.: Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis. Child (1970) 45;243:696-701.
72. SUTHERLAND HW, BEWSHER PD, CORMACK JD et al.: Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis. Child (1974) 49:283-291.
73. COETZEE EJ, JACKSON WP: Oral hypoglycaemics in the first trimester and fetal outcome. S. Afr. Med. J. (1984) 21;65:635-637.
74. ELLIOTT BD, LANGER O, SCHENKER S et al.: Insignificant transfer of glyburide occurs across the human placenta. Am. J. Obstet. Gynecol. (1991) 165:807-812.
75. KOREN G: Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod. Toxicol. (2001) 15:227-229.
76. NIEMI M, BACKMAN JT, NEUVONEN M et al.: Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. (2001) 69:400-406.
77. SMIT JW, HUISMAN MT, VAN TELLINGEN O et al.: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. (1999) 104:1441-1447.
78. LANGER O, CONWAY DL, BERKUS MD et al.: A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. (2000) 19:343:1134-1138.
79. KOREN G: The use of glyburide in gestational diabetes-an ideal example of 'bench to bedside'. Pediatr. Res. (2001) 49:734.
80. LORD JM, FLIGHT IH, NORMAN RJ: Metformin in polycystic ovary syndrome: Systemic review and meta-analysis. Br. Med. J. (2003) 327(7421):951-953.
81. GLUECK CJ, WANG P, KOBAYASHI S et al.: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril. (2002) 77:520-525.
82. COETZEE E, JACKSON W: The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res. Clin. Pract. (1986) 1:281-287.
83. HELLMUTH E, DAMM P, MOLSTED-PEDERSEN L: Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet. Med. (2000) 17:507-511.
84. STEEL JM, CAMPBELL IW: Oral hypoglycaemic agents in 188 diabetic pregnancies. Diabet. Med. (2001) 18:604-605.
85. HAGUE WM, DAVOREN PM, OLIVER D et al.: Contraindications to use of metformin. Metformin may be useful in gestational diabetes. Br. Med. J. (2003) 326:762.
86. SIMMONS D, WALTERS BN, ROWAN JA et al.: Metformin therapy and diabetes in pregnancy. Med. J. Aust. (2004) 180:462-464.
87. HAGUE WM, DAVOREN PM, McINTYRE D et al.: Metformin crosses the placenta: A modulator for fetal insulin resistance. Br. Med. J. (2003) 327:880-881.
88. MOKDAD AH, BOWMAN BA, FORD ES et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA (2001) 12:286:1195-1200.
89. BELL DS: Type 2 diabetes mellitus: what is the optimal treatment regimen? Am. J. Med. (2004) 116(Suppl. 5A):23S-29S.
90. YARIS F, YARIS E, KADIOGLU M et al.: Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol. (2004) 18:619-621.
91. LEBOVITZ HE: α-Glucosidase inhibitors. Endocrinol. Metab. Clin. North Am (1997) 26:539-551.
92. ZARATE A, OCHOA R, HERNANDEZ M et al.: Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Gynecol. Obstet. Mex. (2000) 68:42-45.